A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?

Breast J. 2020 Sep;26(9):1857-1859. doi: 10.1111/tbj.13856. Epub 2020 May 20.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Albumins
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Breast Neoplasms* / drug therapy
  • Capecitabine / adverse effects
  • Female
  • Humans
  • Paclitaxel / adverse effects
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Capecitabine
  • Paclitaxel